Flutamide in the treatment of metastatic carcinoma of the prostate.
Twenty-five patients with metastatic carcinoma of the prostate were treated with Flutamide, a non-steroidal anti-androgen. All patients showed progression; the longest response was 120 weeks. The side effects were nausea, vomiting, breast tenderness and gynaecomastia.